Posted by Michael Wonder on 01 Sep 2022
Antengene announces Xpovia included for reimbursement by the PBS in Australia for the treatment of patients with relapsed and/or refractory multiple myeloma
1 September 2022 - Xpovio (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor approved by the TGA of Australia for patients with relapsed and/or refractory multiple myeloma and in triple class refractory relapsed and/or refractory multiple myeloma.
Antengene today announced that Xpovio (selinexor) in combination with dexamethasone has been PBS Listed for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody (penta-refractory).
